Christian L. J. Ewers
Pharm. Ind. 68, No. 10, 1144-1148 (2006)
Owing to longer development periods combined with increasing R&D expenditure for any New Chemical Entity (NCE), research-based pharmaceutical companies are under increasing cost pressure. The dramatic changes within the past decade are evident in the R&D budgets of the pharmaceutical industry which have almost doubled over this period, whereas the number of NCEs that ...
(File type: PDF • File size: 0.14 MB)
To view a PDF file you need " Adobe Reader" software from Adobe ®. |
|
]
